- Home
- IPSC vs SDST Comparison
IPSC vs SDST Comparison
Compare IPSC & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- SDST
- Stock Information
- Founded
- IPSC 2019
- SDST 2022
- Country
- IPSC United States
- SDST United States
- Employees
- IPSC N/A
- SDST N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- SDST Blank Checks
- Sector
- IPSC Health Care
- SDST Finance
- Exchange
- IPSC Nasdaq
- SDST Nasdaq
- Market Cap
- IPSC 42.2M
- SDST 34.3M
- IPO Year
- IPSC 2021
- SDST N/A
- Fundamental
- Price
- IPSC $0.49
- SDST $0.40
- Analyst Decision
- IPSC Strong Buy
- SDST Buy
- Analyst Count
- IPSC 5
- SDST 2
- Target Price
- IPSC $3.33
- SDST $1.70
- AVG Volume (30 Days)
- IPSC 698.6K
- SDST 1.1M
- Earning Date
- IPSC 08-14-2025
- SDST 08-13-2025
- Dividend Yield
- IPSC N/A
- SDST N/A
- EPS Growth
- IPSC N/A
- SDST N/A
- EPS
- IPSC N/A
- SDST N/A
- Revenue
- IPSC $114,128,000.00
- SDST N/A
- Revenue This Year
- IPSC $1,589.94
- SDST N/A
- Revenue Next Year
- IPSC N/A
- SDST N/A
- P/E Ratio
- IPSC N/A
- SDST N/A
- Revenue Growth
- IPSC 5491.77
- SDST N/A
- 52 Week Low
- IPSC $0.34
- SDST $0.14
- 52 Week High
- IPSC $1.86
- SDST $12.56
- Technical
- Relative Strength Index (RSI)
- IPSC 37.35
- SDST 49.62
- Support Level
- IPSC $0.46
- SDST $0.36
- Resistance Level
- IPSC $0.55
- SDST $0.43
- Average True Range (ATR)
- IPSC 0.04
- SDST 0.03
- MACD
- IPSC -0.00
- SDST -0.00
- Stochastic Oscillator
- IPSC 25.00
- SDST 43.62
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).